Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

ITIF Report: Timely Congressional Reauthorization of Prescription Drug User Fee Act Is Critical for Biomedical Innovation

3/3/2017

0 Comments

 
 Washington, DC — As Congress considers reauthorizing the Prescription Drug User Fee Act (PDUFA) this year, policymakers should recognize the foundational role it plays in America’s biomedical ecosystem by supporting life-sciences innovation and speeding cures, argues the Information Technology and Innovation Foundation (ITIF) in a new report.
 
“User fees help provide the FDA with the resources necessary to make accurate, timely determinations about the safety and efficacy of new drugs,” said Stephen J. Ezell, ITIF’s vice president for global innovation policy and the report’s author.
 
“The user-fee system,” Ezell said, “fosters innovation by ensuring the FDA has the resources and skilled personnel needed to incorporate the latest advances in regulatory science into the drug-approval process.”
 
“This may at first glance seem like a mundane, bureaucratic process, but it is actually a key factor in why America has emerged in recent decades as the world’s leader in life sciences,” he said.  “It is a commonsense policy that Congress should reauthorize with further enhancements to bolster the FDA’s ability to speed cures and monitor safety.”
​The new report — published on February 27 — explains that in 1987 the median approval time from the Food and Drug Administration (FDA) for a new medicine was over two-and-a-half years (33 months) due in large part to a lack of resources at the agency.
 
Since PDUFA passed in 1992 — authorizing the FDA to collect fees from the biopharmaceutical industry as part of applications for regulatory approval of new human drug submissions — the median approval time has fallen to under 10 months, meaning that safe, innovative drugs get to patients faster.
 
The report also explains that this stability provides the predictability innovators need to invest in new cures.
 
In addition to benefiting patients by helping speed cures, PDUFA has also played a supporting role in establishing the United States as the world’s leader in life-sciences innovation, an important sector to the U.S. economy that supports over 4.4 million total jobs directly and throughout its supply chain, with exports of $47 billion in 2015, an amount that has tripled since 2003.
 
As Congress considers reauthorizing this law for the fifth time since 1992, the report urges lawmakers to update the law to accomplish several goals:
 
  • Support the development and application of 21st-century regulatory science approaches to drug development, including creating a pathway for greater use of real-world evidence, supporting innovative clinical-trial approaches, and enhancing biomarker-qualification pathways.
 
  • Direct more attention to patient-focused drug development, including greater effort to incorporate patient perspectives in the drug development and review process, including making greater use of patient-reported outcomes.
 
  • Focus more on supporting rare diseases and breakthrough therapies, including continued application-fee waivers and advanced reviews for medicines that can treat rare diseases, as well as prioritizing the development of breakthrough medicines for patients with life-threatening diseases.
 
  • Enhance post-market safety monitoring of approved drugs, including additional resources for the FDA’s Sentinel system to monitor drugs that have already entered the patient population.
 
Enhance FDA workflow and workforce planning, including financial management and hiring and workforce enhancements.
 
Ezell dismissed arguments suggesting PDUFA has caused the FDA to view the biopharmaceutical industry too much as a “partner” or source of revenue, rather than as an industry over which it has regulatory oversight.
 
“PDUFA isn’t about getting to yes faster. It’s about making a determination in a timely manner about the safety and efficacy of a drug and whether or not it should receive marketing approval,” he said.  
 
The report points out that less than 12 percent of the candidate medicines that make it into Phase I clinical trials are approved by the FDA—half the rate of a decade ago.
 
“The Prescription Drug User Fee Act has played an instrumental role in ensuring the FDA has the necessary personnel and resources at its disposal to make safe, effective, and timely determinations regarding drug applications,” said Ezell,
 
“Policymakers should reauthorize PDUFA in a timely manner to ensure that America’s biopharmaceutical industry can continue to innovate and develop new treatments to help patients live healthier lives.”
 
Read summary.
 
Read report.
 
The Information Technology and Innovation Foundation (ITIF) is an independent, nonpartisan research and educational institute focusing on the intersection of technological innovation and public policy.
 
Recognized as one of the world’s leading science and technology think tanks, ITIF’s mission is to formulate and promote policy solutions that accelerate innovation and boost productivity to spur growth, opportunity, and progress.
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Health Care
    Healthcare
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
10 West Lafayette Street
Trenton, NJ 08608
732-729-9619